Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Weight Loss
Interventions: Erchonia MLS, Placebo Laser; Device
Lead sponsor: Erchonia Corporation; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Fox River Grove, Illinois

Conditions: Prader-Willi Syndrome
Interventions: Pitolisant tablet, Placebo tablet; Drug · Other
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 16 more

Conditions: Asthma
Interventions: Ginger Extract, Placebo; Drug
Lead sponsor: Emily DiMango, MD; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Cocaine Dependence
Interventions: Mifepristone, placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Fracture
Interventions: Vitamin D3, Placebo; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
Interventions: Placebo, PF-06865571, PF-05221304; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 184
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 101 more

Conditions: Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)
Interventions: MET097 Injection, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 29
States / cities: Bessemer, Alabama • Chula Vista, California • Glendale, California + 23 more

Conditions: Diverticulitis
Interventions: Mesalazine, Placebo; Drug
Lead sponsor: Dr. Falk Pharma GmbH; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New Smyrna Beach, Florida

Conditions: Prostate Cancer
Interventions: dutasteride, placebo; Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dyslipidemia
Interventions: PPAR alpha, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 54
States / cities: Hoover, Alabama • Fayetteville, Arkansas • San Diego, California + 51 more

Conditions: Stomatitis
Interventions: CG53135-05, velafermin; Drug
Lead sponsor: CuraGen Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 9
States / cities: La Jolla, California • Denver, Colorado • Miami, Florida + 6 more

Conditions: Acute Coronary Syndromes
Interventions: Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 4,614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 143
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 30
States / cities: Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more

Conditions: Benign Prostatic Hyperplasia
Interventions: botulinum toxin Type A, Normal saline; Drug
Lead sponsor: Allergan; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Alzheimer Disease
Interventions: ONO-2020, Placebo; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 60
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 53 more

Conditions: Diabetes
Interventions: Ginseng, ginsenoside RE, Placebo (sugar pill); Drug · Dietary Supplement
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Kidney Injury
Interventions: CXA-10, CXA-10 placebo; Drug
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: Setanaxib, Pembrolizumab, Placebo; Drug · Biological
Lead sponsor: Calliditas Therapeutics Suisse SA; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Miami Beach, Florida • City of Saint Peters, Missouri • Creve Coeur, Missouri + 2 more

Conditions: Treatment Resistant Depression
Interventions: PCN-101, Placebo; Drug
Lead sponsor: Perception Neuroscience; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 13
States / cities: Little Rock, Arkansas • Garden Grove, California • La Jolla, California + 10 more

Conditions: Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases, Tamoxifen, Estrogen Receptor Antagonist, Hormone Antagonists, Estrogens
Interventions: Tamoxifen, Placebo Oral Tablet; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Melanoma
Interventions: GSK 2132231A, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 74
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 59 more

Conditions: Parkinson's Disease
Interventions: FB-101, Placebo; Drug
Lead sponsor: 1ST Biotherapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: CS-8080, placebo tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Hormone Refractory Prostate Cancer
Interventions: AT-101, prednisone and docetaxel, placebo, prednisone and docetaxel; Drug
Lead sponsor: Ascenta Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 24
States / cities: Colorado Springs, Colorado • New Port Richey, Florida • Ocoee, Florida + 21 more

Search by objective public record fields.

Study to See How Low Level Laser Light Affects Subcutaneous Fat Around the Hips and Waist

A Study of Pitolisant in Patients With Prader-Willi Syndrome

Ginger's Therapeutic Potential in Asthma

Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients

Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis

Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer

A Study in People With Abnormal Fat Levels in the Blood

Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

A Clinical Trial of Ginseng in Diabetes

Oral CXA-10 Study in Healthy Volunteers

A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD

Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

Effects of Multiple Doses of CS-8080 in Healthy Volunteers

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)